Chiltern Appoints Steve Albrecht to Support Further Expansion in ...( LONDON Oct. 9 /- Chiltern a leadi...),Health

LONDON, Oct. 9 /PRNewswire/ -- Chiltern, a leading global clinical research organization, has announced the appointment of Steve Albrecht to the role of Director, Business Operations, Late Phase. Steve Albrecht brings over 20 years of CRO industry experience to his new appointment; previously he held executive management positions with other major CROs and recently Registrat in late phase development.

Mr. Albrecht will be providing leadership for the development, implementation and execution of Chiltern's Late Phase strategies.

"I am delighted to join the current excellent staff at Chiltern," said Steve "and I look forward to further developing the Late Phase division in order to provide our sponsors with the best available options for the conduct of their Phase IIIb/IV studies. Post marketing studies pose an excellent opportunity to combine the knowledge gained in early phase development with well-designed and implemented late phase programs. Today, FDA and the pharmaceutical industry are mandating an ever-increasing number of post-marketing trials to follow products in a real-world setting. These studies require high quality standards yielding high quality data."

"I am delighted that Steve has joined Chiltern," commented James Esinhart, Executive Vice President, Biometrics & Late Phase. "Steve's strong background in Late Phase will add strength to our group and provide sponsors with services in the design and execution of both commercial programs and risk management programs for their marketed products."

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1000 people with 18 offices across the United States, Europe and in India. Chiltern provides services including Early Phase, Global Clinical De
'/>"/>